Printer Friendly

Healthgrades COVID-19 Patient Confidence Study Shows Consumer Confidence Towards Healthcare Providers on the Rise.

M2 PHARMA-May 22, 2020-Healthgrades COVID-19 Patient Confidence Study Shows Consumer Confidence Towards Healthcare Providers on the Rise

(C)2020 M2 COMMUNICATIONS

- Patient confidence in visiting healthcare providers is at the highest levels since March 27, according to a new study conducted by Healthgrades, a resource that connects consumers, physicians and health systems, in partnership with Infosurv.

The COVID-19 Patient Confidence Study, a weekly measure of consumer attitudes and behavior, shows that consumer confidence is at the highest levels since the onset of COVID-19.

72% of patients have reported that they are not delaying a doctor visit to discuss a condition. In addition, the majority of patients expect to go to the HCP in the next two months or sooner, while only 37% expected to go in the next two months on April 30.

86% of consumers are comfortable visiting healthcare providers, over twice the confidence of visiting a restaurant or the 36% comfortable attending a public gathering such as a rock concert or sports event.

Physician search has significantly increased across the country from late March. For example, in Nevada, there was an increase of 129%; in Texas, there was an increase of 111%; and in New York an increase of 114%.

The research also shows that telemedicine has played an important role in delivering care. According to the survey, 30% of respondents have participated in telemedicine in the past 3 months and 83% are open to interacting with their care provider virtually.

Infosurv Research is a boutique research agency based in Atlanta, GA.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2020 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2020 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 22, 2020
Words:265
Previous Article:IMV Selects Vaccine Candidate Against COVID-19 to Advance into Human Clinical Studies.
Next Article:Acella Pharmaceuticals recalls 13 lots of 30-mg, 60-mg and 90-mg NP Thyroid.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |